Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation
ACS Omega · 04.08.2026 · 11 (30) · 44712-44728
DOI: 10.1021/acsomega.6c00415 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 21.07.2026. Verfasst von Pei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yongkang First People's Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou 310053, P. R. China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Commission of Zhejiang Province, Medical and Health Research Project of Zhejiang Province, National Health Commission of the People's Republic of China.
Abstract (Originalsprache)
Aurora kinase A (AURKA) is a pivotal driver of malignant progression and poor prognosis in triple-negative breast cancer (TNBC). In this study, we developed a cascaded AI-driven virtual screening pipeline, integrating sequence-based affinity prediction (PSICHIC), equivariant deep learning docking (KarmaDock), and geometric rescoring (DeepDock) to identify novel AURKA inhibitor candidates. From an in-house 160,000-compound screening library assembled from commercially available collections, three leads (compounds 3, 5, and 8) were selected and subsequently validated via HTRF biochemical assays, exhibiting potent enzymatic inhibition with IC50 values of 157 nM, 21.64 nM, and 46.03 nM, respectively. Cell-based assays demonstrated that compound 3 produced stronger short-term cell-growth inhibition in MDA-MB-231 (TNBC) cells compared to clinical benchmarks MLN8237 and CCT241736, whereas compounds 3 and 5 showed cell-growth inhibition in NIH/3T3 cells within the same concentration range as the reference inhibitors. Triplicate 500 ns molecular dynamics simulations supported stable binding modes of the identified leads in the AURKA binding pocket. Additional computational analyses further provided supportive information for subsequent lead optimization. This study provides a transparent and open-source workflow for AI-assisted identification of AURKA-active chemotypes.
Autor:innen und Institutionen
- Affiliated Yongkang First People's Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou 310053, P. R. China.
- Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou 311399, Zhejiang, China.
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
ORCID-Profile: Xiangwei Xu, Wenhai Huang
Förderung
- Health Commission of Zhejiang Province
- Medical and Health Research Project of Zhejiang Province
- National Health Commission of the People's Republic of China
Zitieren
APA
Liu, P., Liu, Y., Zhang, X., Chen, R., Pan, Y., Xu, X., & Huang, W. (2026). Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation. ACS Omega, 11(30), 44712-44728. https://doi.org/10.1021/acsomega.6c00415
Vancouver
Liu P, Liu Y, Zhang X, Chen R, Pan Y, Xu X, et al. Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation. ACS Omega. 2026;11(30):44712-44728. doi:10.1021/acsomega.6c00415
BibTeX
@article{Liu2026,
author = {Liu, Pei and Liu, Yanqing and Zhang, Xin and Chen, Runmei and Pan, Youlu and Xu, Xiangwei and Huang, Wenhai},
title = {Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {30},
pages = {44712--44728},
doi = {10.1021/acsomega.6c00415}
}
EUVIMED